In contrast, depletion, or inhibition of NAMPT resulted in antitumor effects by elevating levels of ROS in non-small cell lung cancer (NSCLC) (33), glioblastoma (34), prostate cancer (35), breast cancer (29), and colon cancer (32). This evidence concerns the gene NAMPT and non-small cell lung carcinoma.